Foley Partner Paul Broude authored an article titled “The IPO Window Is Opening” in the March 2010 issue of MX: Medtech Executive. Broude examines the reasons for a device company to consider an initial public offering for its growth plans, stating that 2010 may bring the promise of IPOs for medical device companies to fund clinical trials, regulatory approvals, and the protection of the company’s intellectual property. He adds that going public enables some medical device and life science companies to continue growing while creating an exit vehicle for management and other shareholders.
Author(s)
Related Insights
July 11, 2025
Foley Viewpoints
Department of Justice Launches Program to Reward Antitrust Whistleblowers with Shares of Criminal Fines
On July 8, 2025, the U.S. Department of Justice, Antitrust Division (“Antitrust Division”) announced a new “Whistleblower Rewards…
July 23, 2025
Events
Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact
Foley partner Monica Chmielewski, vice chair of the firm’s Health Care Practice Group, is speaking in Strafford’s upcoming webinar titled “Healthcare Supply Chain Compliance Challenges: Vendor Management, Contract Negotiation, Tariff Impact” on July 23.
September 30, 2025
Events
FDA Regulation of AI-Enabled Medical Devices
Foley partner Kyle Faget, co-chair of the firm’s Medical Devices Area of Focus, is speaking at the American Bar Association Health Law Section’s Healthcare Delivery & Innovation Conference on September 30.